{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-041049","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.513368+00:00","generated_at":"2026-05-22T05:43:26.998959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances","bullets":["Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).","Cash and equivalents $7.3M at Mar 31, 2025, down from $10.0M at Dec 31, 2024; 1.9M common shares outstanding.","Appointed Dr. James Ferguson as CMO in February 2025 to lead clinical development and business development.","FDA Type D meeting in Feb 2025 provided guidance for Phase 3 tecarfarin trial; Abbott collaboration announced for TECH-LVAD trial.","Completed API manufacturing transfer from Asia to U.S. CDMO; LVAD market research projects near doubling by 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-041049","json":"https://secwatch.observer/filing/0001213900-25-041049.json","markdown":"https://secwatch.observer/filing/0001213900-25-041049.md","text":"https://secwatch.observer/filing/0001213900-25-041049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/0001213900-25-041049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/ea0241397-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:43:26.998959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}